Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
AIM: Nonadherence to glucagon-like peptide-1 receptor agonists (GLP1 RAs) is relatively common among patients with type 2 diabetes mellitus (T2DM). This study sought to identify reasons why patients discontinue GLP1 RAs. MATERIALS AND METHODS: Retrospective data from the Adelphi Diabetes Disease Specific Programme were used. Physicians managing patients with T2DM were surveyed via face-to-face interviews, and patients treated for T2DM were surveyed via self-completed questionnaires. Patient data were stratified by current versus prior GLP1 RA use. RESULTS: Physicians (n=443) most frequently reported inadequate blood glucose control (45.6%), nausea/vomiting (43.8%), and gastrointestinal (GI) side effects (36.8%) as reasons for GLP1 RA discontinuation. Patients (n=194) reported the GI-related issues "Made me feel sick" (64.4%) and "Made me throw up" (45.4%) as their top reasons for discontinuation. The most common problems reported (excluding cost) for those currently using GLP1 RAs were "Prefer oral medication over injections" (patients 56%, physicians 32.6%), "Made me feel sick" (patients 38.1%, physicians 16.3%), and "Did not help lose weight" (patients 25.4%, physicians 18%). The most bothersome problems for patients globally (frequency reporting very/extremely bothersome) (excluding cost) were "Difficult to plan meals around" (55.6%), "Made me throw up" (51.6%), and "Caused weight gain" (50%). CONCLUSION: Both patients and physicians reported GI-related issues as a prominent factor, but disparities between patient experiences and physician perceptions were revealed, suggesting gaps in physician-patient communication. Understanding patients' expectations of GLP1 RAs and physicians' patient-management practices may help increase GLP1 RA adherence and thereby potentially enhance diabetes care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For patients taking these medications for the treatment of obesity, there may be a particular reluctance to continue when weight loss plateaus or weight loss goals are reached”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cost has consistently been cited as one of the most common barriers toward initiating and continuing GLP1-RA treatment, though there are still limited data on GLP1-RAs used solely for weight management.75,97,106”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the largest cross-sectional survey of GLP-1 RA discontinuation in routine practice to date, both physicians and patients converged on GI symptoms as a leading cause of treatment cessation, although the relative emphasis differed [54].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Surveyed physicians (n = 443) most frequently cited inadequate glycemic control (45.6%), nausea or vomiting (43.8%), and other GI side effects (36.8%) as reasons for stopping therapy in their patients; surveyed patients in turn most frequently cited nausea (64.4%) and vomiting (45.4%) as their principal reasons for abandoning treatment.”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [54]
In the citing paper
“In clinical practice, GI AEs (most commonly nausea) are known to be a common reason for discontinuation of GLP‐1RA treatment. 41”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“AEs with GLP1 RAs to be GI events, including diarrhea, nausea, and vomiting.(25) Given time, these common AEs usually subside.”
Anderson, P., Benford, M., Harris, N., Karavali, M., & Piercy, J. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802457040 · Cited by 522 · cited 2×
“A full description of the methodology has been published previously.(7)”
Self-citationA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365 · cited 1×
“For example, in clinical trials, <5% of patients discontinued a GLP1 RA due to GI effects; however, higher rates, between 5% and 10%, have been observed in clinical practice.(23,24) Clinical trials have reported the most common Figure 2 Reasons for GLP1 RA discontinuation in the past 6 months, ranked by frequency.”
GLP-1 receptor agonists: a review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282 · cited 1×
“Although clinical trials have demonstrated that GLP1 RAs are effective at reducing HbA 1c levels, these trials have also highlighted the differences in the type, frequency, and severity of adverse events (AEs) compared to insulin and among drugs within the GLP1 RA class.(20,21) Our results suggest the outcomes of thes…”
Higgins, V., Piercy, J., Roughley, A., Milligan, G., Leith, A., Siddall, J., & Benford, M. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s120101 · Cited by 260
Self-citationBabineaux, S. M., Curtis, B., Holbrook, T., Milligan, G., & Piercy, J. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010352 · Cited by 253 · cited 1×
“Data used for this analysis are more likely to provide a representative, real-world sample of patients with T2DM and real-world patient behavior than randomized clinical trial data.(10,22) For example, in clinical trials, <5% of patients discontinued a GLP1 RA due to GI effects; however, higher rates, between 5% and 1…”
Self-citation7. Approaches to Glycemic Treatment
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s010 · Cited by 225
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156 · cited 1×
“16–19 This study suggests that this is the case for GLP1 RA users, as we found GI issues were three of the top five reasons for GLP1 RA discontinuation for patients across both geographic regions, indicating that patients may place more importance on factors that interrupt daily routines and…”
Elliott, L., Fidler, C., Ditchfield, A., & Stissing, T. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0157-z · Cited by 135 · cited 1×
“Data used for this analysis are more likely to provide a representative, real-world sample of patients with T2DM and real-world patient behavior than randomized clinical trial data.(10,22) For example, in clinical trials, <5% of patients discontinued a GLP1 RA due to GI effects; however, higher rates, between 5% and 1…”
Saunders, C., Byrne, C. D., Guthrie, B., Lindsay, R. S., McKnight, J. A., Philip, S., Sattar, N., Walker, J. J., Wild, S. H., & on behalf of the Scottish Diabetes Research Network Epidemiology Group (2013) · Diabetic Medicine · doi:10.1111/dme.12047 · Cited by 122 · cited 1×
“Additionally, up to 90% of patients with T2DM screened did not qualify for trials, and 49% of patients with newly diagnosed T2DM were found to be ineligible.(26) This finding underscores the importance of obtaining and using real-world data when possible, while remaining cautious when applying clinical trial findings…”
Cited by
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146353 · Cited by 256
“However, although the GLP-1RA class has improved the standard of care, many patients still do not reach their glycemic targets (10), and thus, there remains a need to identify agents capable of complementing the actions of GLP-1RAs.”
BackgroundWharton, S., Davies, M., Dicker, D., Lingvay, I., Mosenzon, O., Rubino, D. M., & Pedersen, S. D. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2021.2002616 · Cited by 236
“However, GI side effects remain the most common reason for patients discontinuing treatment [23].”
BackgroundBorner, T., Geisler, C. E., Fortin, S. M., Cosgrove, R., Alsina-Fernandez, J., Dogra, M., Doebley, S., Sanchez-Navarro, M. J., Leon, R. M., Gaisinsky, J., et al. (2021) · Diabetes · doi:10.2337/db21-0459 · Cited by 202
“Food and Drug Administration-approved GLP-1–based therapeutics elicit nausea and vomiting in a significant percentage of patients, which represent primary reasons for treatment discontinuation (4).”
BackgroundShould metformin remain the first-line therapy for treatment of type 2 diabetes?
Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820980225 · Cited by 181
Wharton, S., Calanna, S., Davies, M., Dicker, D., Goldman, B., Lingvay, I., Mosenzon, O., Rubino, D. M., Thomsen, M., Wadden, T. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14551 · Cited by 200
“In clinical practice, GI AEs (most commonly nausea) are known to be a common reason for discontinuation of GLP-1RA treatment.(41)”
BackgroundAdhikari, R., Jha, K., Dardari, Z., Heyward, J., Blumenthal, R. S., Eckel, R. H., Alexander, G. C., & Blaha, M. J. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023811 · Cited by 166
“49 Future initiatives to foster uptake among cardiologists should specifically consider these 2 potential barriers.”
Anderson, P. E., Higgins, V., de Courcy, J. J., Doslikova, K., Davis, V. A., Karavali, M., & Piercy, J. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2279679 · Cited by 157
Self-citationMozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“…loss of significant muscle mass and bone density [4]; high discontinuation rates (e.g., 50 – 67 %% at one year and 85 % at two years [5 – 8]) that may relate to side effects, costs, variable individual efficacy, or patient preferences [5,9]; and limited public and clinician knowledge on…”
Gulak, M. A., & Murphy, P. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-023-02521-3 · Cited by 153
“Gastrointestinal symptoms such as nausea, vomiting, and diarrhea(10) are the most common side effects of GLP-1 RAs and are some of the most common reasons for cessation of the medication.(11) Interestingly, the patient in this report only had mild, self-limited diarrhea during the first week of starting the medication…”
BackgroundSaxena, A. R., Frias, J. P., Brown, L. S., Gorman, D. N., Vasas, S., Tsamandouras, N., & Birnbaum, M. J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.14493 · Cited by 149
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
“GLP-1s are separately approved for type 2 diabetes and chronic kidney disease, which are not the focus of this Advisory.”
Khoo, J., Hsiang, J. C., Taneja, R., Koo, S., Soon, G., Kam, C. J., Law, N., & Ang, T. (2019) · Liver International · doi:10.1111/liv.14065 · Cited by 136
Aroda, V. R., Aberle, J., Bardtrum, L., Christiansen, E., Knop, F. K., Gabery, S., Pedersen, S. D., & Buse, J. B. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01127-3 · Cited by 126
Berg, S., Stickle, H., Rose, S. J., & Nemec, E. C. (2025) · Obesity Reviews · doi:10.1111/obr.13929 · Cited by 111
“8,9 In addition, GLP-1RA therapy can be cost-prohibitive 10 as many insurance companies will not cover GLP-1RAs without an existing diagnosis of type 2 diabetes mellitus or cardiac risk factors.”
The therapeutic potential of GLP‐1 receptor biased agonism
Jones, B. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15497 · Cited by 98
“Real-world experience suggests the extent of the problem may not be fully represented in clinical trials (Sikirica et al., 2017).”
BackgroundBoye, K., Ross, M., Mody, R., Konig, M., & Gelhorn, H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14244 · Cited by 88
“0%).(16) However, to date, no known published research has directly compared a once-daily oral medication to once-weekly injectable administration.”
BackgroundGLP-1 agonists for weight loss: pharmacology and clinical implications.
Moore, P. W., Malone, K., VanValkenburg, D., Rando, L. L., Williams, B. C., Matejowsky, H. G., Ahmadzadeh, S., Shekoohi, S., Cornett, E. M., & Kaye, A. D. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02394-w · Cited by 86
Blonde, L., Rosenstock, J., Del Prato, S., Henry, R., Shehadeh, N., Frias, J., Niemoeller, E., Souhami, E., Ji, C., & Aroda, V. R. (2019) · Diabetes Care · doi:10.2337/dc19-1357 · Cited by 85
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933433 · Cited by 82
Adherence and persistence rates of major antidiabetic medications: a review
Lee, D. S. U., & Lee, H. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00785-1 · Cited by 72
One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice
Gasoyan, H., Pfoh, E. R., Schulte, R., Le, P., Butsch, W. S., & Rothberg, M. B. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.33326 · Cited by 71
Karakasis, P., Patoulias, D., Pamporis, K., Stachteas, P., Bougioukas, K. I., Klisic, A., Fragakis, N., & Rizzo, M. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155710 · Cited by 66
Hanefeld, M., Fleischmann, H., Siegmund, T., & Seufert, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00855-5 · Cited by 71
Merkel, R., Hernandez, N. S., Weir, V. R., Zhang, Y., Caffrey, A., Rich, M. T., Crist, R. C., Reiner, B. C., & Schmidt, H. D. (2025) · Science Advances · doi:10.1126/sciadv.adr5051 · Cited by 79
“In addition, GLP-1R agonists are known to decrease food intake and produce nausea/emesis in both drug-naïve rodents and humans ( 4 , 17 – 19 ).”
The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
Hayes, M. R., Borner, T., & De Jonghe, B. C. (2021) · Diabetes · doi:10.2337/dbi21-0004 · Cited by 64
“cancers, diabetes, cystic fibrosis, pregnancy) it is clear that the 5-HT3R and NK1R antagonists are suboptimal for the total control of malaise (12-14), suggesting that there are other underlying neural substrates involved in the control of nausea and emesis.”
BackgroundSystematic review of incretin therapy during peri-operative and intensive care
Hulst, A. H., Plummer, M. P., Hollmann, M. W., DeVries, J. H., Preckel, B., Deane, A. M., & Hermanides, J. (2018) · Critical Care · doi:10.1186/s13054-018-2197-4 · Cited by 63
“Although compliance with GLP-1 receptor agonists is relatively good in ambulant patients with T2DM, the primary reason for discontinuation of therapy is gastrointestinal discomfort, particularly nausea and vomiting [36, 37].”
BackgroundManagement of metabolic-associated fatty liver disease: The diabetology perspective
Jeeyavudeen, M. S., Khan, S. K., Fouda, S., & Pappachan, J. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i1.126 · Cited by 54
Ghidewon, M., Wald, H. S., McKnight, A. D., De Jonghe, B. C., Breen, D. M., Alhadeff, A. L., Borner, T., & Grill, H. J. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14663 · Cited by 51
“Countless medical reports highlight nausea and emesis as the principal reported side effect and major reason for treatment discontinuation with existing GLP-1-receptor-based agents, including semaglutide.(50,51) Importantly, these adverse effects are caused by direct central activation of various GLP1-receptor-express…”
BackgroundGLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2192865 · Cited by 56
“related study indicated that over 60% of patients cite feelings of nausea or GIT discomfort as the primary reason for discontinuation of GLP-1 mimetics [40].”
BackgroundSamms, R. J., Sloop, K. W., Gribble, F. M., Reimann, F., & Adriaenssens, A. E. (2021) · Diabetes · doi:10.2337/dbi21-0002 · Cited by 49
Borner, T., Tinsley, I. C., Doyle, R. P., Hayes, M. R., & De Jonghe, B. C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15647 · Cited by 49
Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
Perreault, L., Rodbard, H. W., Valentine, V., & Johnson, E. L. (2019) · Advances in Therapy · doi:10.1007/s12325-018-0868-9 · Cited by 49
Witkowski, M., Wilkinson, L., Webb, N., Weids, A., Glah, D., & Vrazic, H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0424-2 · Cited by 45
“with GLP-1 RAs (due to their glucose-dependent mechanism of action) and it is not typically cited as a reason for discontinuation of GLP-1 RAs [72].”
BackgroundLavu, M. S., Porto, J. R., Hecht, C. J., Kaelber, D. C., Sculco, P. K., Heckmann, N. D., & Kamath, A. F. (2024) · The Journal of Arthroplasty · doi:10.1016/j.arth.2024.06.008 · Cited by 47
Nuhoho, S., Gupta, J., Hansen, B. B., Fletcher-Louis, M., Dang-Tan, T., & Paine, A. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00706-y · Cited by 41
“One of the most commonly cited reasons for treatment discontinuation with GLP-1 RAs is GI AEs [88, 89].”
BackgroundLassen, M. C. H., Johansen, N. D., Modin, D., Catarig, A., Vistisen, B. K., Amadid, H., Zimmermann, E., Gislason, G., & Biering‐Sørensen, T. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15872 · Cited by 40
“A qualitative study 34 based on data from both Europe and the United States investigated the reasons for discontinuing GLP-1RA therapy and found that cost was one of the predominant reasons for stopping therapy in the United States, but less so in Europe.”
Guerci, B., Charbonnel, B., Gourdy, P., Hadjadj, S., Hanaire, H., Marre, M., & Vergès, B. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.006 · Cited by 40
Consoli, A., Formoso, G., Baldassarre, M. P. A., & Febo, F. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1428305 · Cited by 37
“Although they are often minimized by a dose-escalating initiation [51], they occur in at least 25% of patients and are a major cause for drug discontinuation [52,53].”
BackgroundCorrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis
Borner, T., Workinger, J. L., Tinsley, I. C., Fortin, S. M., Stein, L. M., Chepurny, O. G., Holz, G. G., Wierzba, A. J., Gryko, D., Nexø, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107768 · Cited by 39
Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
Wojtara, M., Mazumder, A., Syeda, Y., & Mozgała, N. (2023) · Advances in Medicine · doi:10.1155/2023/9946924 · Cited by 36
“Existing GLP-1 receptor agonist therapies typically require subcutaneous administration which may be inconvenient for or not preferred by some patients, resulting in reduced adherence [35].”
Amin, N. B., Frederich, R. C., Tsamandouras, N., Haggag, A. Z., Schuster, T., Żmuda, W., Palmer, A., Vasas, S., Buckley, G., Smith, T. R., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16005 · Cited by 37
Porto, J. R., Lavu, M. S., Hecht, C. J., Kaelber, D. C., Sculco, P. K., Heckmann, N. D., & Kamath, A. F. (2025) · Orthopaedic Journal of Sports Medicine · doi:10.1177/23259671241297157 · Cited by 38
“12,13,23,26,34 Previous studies 28,33 have reported an inherent rate of failure for GLP-1-RAs and poor long-term adherence, with Weiss et al 33 reporting 50.9% adherence at 12 months and 47.4% at 24 months.”
InfluentialRea, F., Ciardullo, S., Savaré, L., Perseghin, G., & Corrao, G. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109035 · Cited by 33
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J. P., Butsch, W. S., Christensen, S. M., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2026.100269 · Cited by 41
Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes
Ng, E., Shaw, J. E., Wood, A. J., Maple-Brown, L. J., & Hare, M. J. L. (2022) · Australian Journal of General Practice · doi:10.31128/ajgp-07-21-6057 · Cited by 30
Giorgino, F., Caruso, I., Moellmann, J., & Lehrke, M. (2020) · Metabolism · doi:10.1016/j.metabol.2019.154045 · Cited by 26
Giorgino, F., Caruso, I., & Napoli, R. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108478 · Cited by 24
Alexopoulos, A.-S., & Buse, J. B. (2019) · Metabolism · doi:10.1016/j.metabol.2019.06.012 · Cited by 24
“Real-world persistence to GLP-1 RAs varies by study, but is in the range of 47% to 80%, and tends to be higher for dulaglutide than for exenatide or liraglutide [4,42].”
BackgroundDash, S. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15829 · Cited by 24
“5,6 We review the effectiveness of lifestyle interventions for T2D and obesity as well as the rationale for initiating GLP-1RA pharmacotherapy.”
Chen, L., Yun, Y., Guo, S., Wang, X., Xiong, M., Zhao, T., Xu, T., Shen, J., Xie, X., & Wang, K. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00320 · Cited by 24
The antiemetic actions of GIP receptor agonism
Borner, T., Jonghe, B. C. D., & Hayes, M. R. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00330.2023 · Cited by 28
McGill, J. B., Hirsch, I. B., Parkin, C. G., Aleppo, G., Levy, C. J., & Gavin, J. R. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01569-8 · Cited by 28
“…cross-sectional survey of 449 primary care physicians and 352 diabetologists/ endocrinologists, the reasons most frequently reported for discontinuation of GLP-1 RA therapy were lack of blood glucose control (45.6%), nausea/vomiting (43.8%), and other gastrointestinal (GI) side effects (36.8) [41].”
BackgroundInfluentialTransforming steatotic liver disease management: The emerging role of GLP-1 receptor agonists
Jensen, E., Israelsen, M. E., & Krag, A. A. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000561 · Cited by 25
Yammine, L., Kosten, T. R., Pimenova, M., & Schmitz, J. M. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.01.033 · Cited by 24
Rayner, C. K., Wu, T., Aroda, V. R., Whittington, C., Kanters, S., Guyot, P., Shaunik, A., & Horowitz, M. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14202 · Cited by 23
“Of 194 patients who were surveyed in the same study, nausea and vomiting were two major reasons for GLP-1 RA discontinuation, being reported by 64% and 45% of patients, respectively.(10)”
BackgroundWright, E. E., Roberts, G. J., Chuang, J. S., Nabutovsky, Y., Virdi, N., & Miller, E. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0015 · Cited by 22
“45,46 However, perhaps the most important factor is diminishing ef fi cacy in maintaining optimal glucose control.”
Klein, K. R., Clemmensen, K. K. B., Fong, E., Olsen, S., Abrahamsen, T., & Lingvay, I. (2024) · Diabetes Care · doi:10.2337/dc23-1791 · Cited by 22
Saldívar-Cerón, H. I., Vargas-Camacho, J. A., León‐Cabrera, S., Briseño-Díaz, P., Castañeda-Ramírez, A. E., Muciño-Galicia, A. E., & Díaz-Domínguez, M. R. (2025) · Scientia Pharmaceutica · doi:10.3390/scipharm93020026 · Cited by 25
Aranäs, C., Caffrey, A., Edvardsson, C. E., Schmidt, H. D., & Jerlhag, E. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.07.001 · Cited by 30
“GLP-1R activation has been shown to produce emesis (Sikirica et al., 2017).”
Smits, M. M., & Holst, J. J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3699 · Cited by 25
“41 Moreover, 40% of patients stopped because they preferred oral medication over injectables, whereas 13% had trouble with the costs.”
BackgroundRabbani, N., & Thornalley, P. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111905 · Cited by 25
Polonsky, W. H., Gamble, C. L., Iyer, N. N., Martin, M. L., & Hamersky, C. M. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0025 · Cited by 23
Why are we still in need for novel anti-obesity medications?
Novikoff, A., Grandl, G., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101098 · Cited by 22
“5 – 7 Therefore, a signi fi cant discrepancy between discontinuation rates reported in clinical trials and those observed in real-world settings seems apparent.”
Handelsman, Y., Chovanes, C., DEX, T. A., Giorgino, F., SKOLNIK, N., Souhami, E., Stager, W., Niemoeller, E., & Frías, J. P. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.11.009 · Cited by 24
Buckeridge, C., Tsamandouras, N., Carvajal‐Gonzalez, S., Brown, L. S., Hernandez‐Illas, M., & Saxena, A. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15643 · Cited by 20
Central mechanisms of emesis: A role for GDF15
Borner, T., Pataro, A. M., & Jonghe, B. C. D. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14886 · Cited by 24
“20 21-26 Exogenous GDF15 administration profoundly reduces food intake and body weight in multiple species, 27-33 and similarly, overexpression of GDF15 in mice results in chronic hypophagia and a lean phenotype, 34 whereas knockout (KO) of GDF15 results in increased adiposity.”
Shiomi, M., Takada, T., Tanaka, Y., Yajima, K., Isomoto, A., Sakamoto, M., & Otori, K. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12900 · Cited by 20
Van, J. T., Frías, J. P., Bonora, E., Raha, S., Meyer, J., Jung, H., Cox, D., Кониг, М., Peleshok, J. C., & Bethel, M. A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01140-9 · Cited by 20
“Patients’ reports of tolerability concerns contribute to poor treatment adherence [23, 31].”
BackgroundThe role of GIPR in food intake control
James-Okoro, P.-P., Lewis, J. E., Gribble, F. M., & Reimann, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1532076 · Cited by 23
Obesity and its management in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Alvarez, J. A., Baker, J. C., Bruni, V., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Domenico, F. D., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109045 · Cited by 21
Ishii, H., Hansen, B. B., Langer, J., & Horio, H. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00985-w · Cited by 19
“On the basis of experiences with insulin, the injectable route of administration may discourage some patients and healthcare providers from using these agents when oral glucose-lowering therapies are available [10, 11].”
BackgroundBoccia, L., Borner, T., Ghidewon, M. Y., Kulka, P., Piffaretti, C., Doebley, S. A., Jonghe, B. C. D., Grill, H. J., Lutz, T. A., & Foll, C. L. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101444 · Cited by 18
“This was expected given the wealth of literature reporting nausea and emesis as the principal side effects of existing GLP-1 therapeutics [73] and top reasons for treatment discontinuation [74].”
BackgroundBorner, T., Pataro, A. M., Doebley, S. A., Furst, C. D., White, A. D., Gao, S. X., Chow, A., Sanchez-Navarro, M. J., Ghidewon, M. Y., Halas, J. G., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu1589 · Cited by 21
“Strategies to reduce side effects, such as slow dose escalation, unfortunately do not fully mitigate nausea, vomiting, and gastrointestinal (GI) distress, which are the primary reasons for treatment discontinuation ( 5 ).”
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 22
Shah, E., Al-Shiab, R., Abdo, A., Özbek, L., Covic, A. C., & Kanbay, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70713 · Cited by 17
Fatima, H., Rangwala, H. S., Mustafa, M. S., Shafique, M. A., Abbas, S. R., Rizwan, A., Ahmad, T. K. F., & Arshad, A. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s439587 · Cited by 17
Merkel, R., Moreno, A., Zhang, Y., Herman, R. J., Nathan, J. B., Zeb, S., Rahematpura, S., Stecyk, K. S., Milliken, B. T., Hayes, M. R., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.10.026 · Cited by 17
Scragg, J., Koutoukidis, D. A., Dirksen, C., Heitmann, B. L., & Jebb, S. A. (2025) · Med · doi:10.1016/j.medj.2025.100805 · Cited by 16
Masuda, Y., Ohbayashi, K., & Iwasaki, Y. (2025) · Diabetology International · doi:10.1007/s13340-025-00819-9 · Cited by 17
Optimizing GLP-1 therapies for obesity and diabetes management
Noronha, J. C., Gaal, L. F. V., Neeland, I. J., Fitch, A., Pfeiffer, A. F. H., Chiavaroli, L., Kendall, C. W. C., & Sievenpiper, J. L. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100222 · Cited by 20
“Because GI symptoms are the leading cause of treatment discontinuation [10,12], implementing preventive and management strategies is essential to maximize adherence and therapeutic benefit.”
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 23
“Aversion to injections and the burden of frequent dosing are other reasons for reduced adherence 38 .”
InfluentialLyons, S. A., & Beaudry, J. L. (2023) · Endocrinology · doi:10.1210/endocr/bqad153 · Cited by 18
Scheen, A. J. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2354885 · Cited by 19
“However, disparities between patient experiences and physician perceptions were revealed, suggesting gaps in physician – patient communication [64].”
BackgroundBoye, K. S., Shinde, S., Kennedy-Martin, T., Robinson, S., & Thieu, V. T. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s328583 · Cited by 18
“Furthermore, in a European cross-sectional survey, 25% of individuals who had discontinued GLP-1 RAs in the previous 6 months indicated that they did so because treatment “did not help me lose weight”.(51) It should be noted, however, that there is also evidence for treatment discontinuation due to weight loss.”
BackgroundLuo, J., Gabriel, N., Korytkowski, M. T., Hernandez, I., & Gellad, W. F. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109855 · Cited by 16
Winkley, K., Upsher, R. J., Polonsky, W. H., & Holmes‐Truscott, E. (2019) · Diabetic Medicine · doi:10.1111/dme.14214 · Cited by 18
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
“Clinical trials have revealed treatment discontinuation rates ranging from 5% to 15% [120].”
Practical guidance for use of oral semaglutide in primary care: a narrative review
Morales, J., Shubrook, J. H., & Skolnik, N. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1788340 · Cited by 14
Oral GLP1 Analog: Where Does the Tide Go?
Gardner, H. M., & Hamdy, O. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420984130 · Cited by 15
McCrimmon, R. J., Lamotte, M., Ramos, M., Alsaleh, A. J. O., Souhami, E., & Lew, E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01156-1 · Cited by 16
Brixner, D. I., Edelman, S. V., Sieradzan, R., & Gavin, J. R. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01598-3 · Cited by 16
“The need for basal-bolus insulin therapy may also arise earlier in individuals who cannot tolerate the side effects (e.g., gastrointestinal) of GLP-1 RA [8] or afford these medications due to inadequate insurance coverage or socioeconomic status.”
BackgroundKushner, P., Anderson, J. E., Simon, J., Boye, K. S., Ranta, K., Torcello-Gómez, A., & Levine, J. A. (2023) · Clinical Diabetes · doi:10.2337/cd22-0029 · Cited by 14
Cho, Y. K., Lee, J., Kim, H. S., Park, J., Jung, C. H., & Lee, W. J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00881-3 · Cited by 14
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Novikoff, A., & Müller, T. D. (2024) · Physiology · doi:10.1152/physiol.00032.2023 · Cited by 15
Comoglio, R. H., & Vidal, X. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13553 · Cited by 16
Home, P. D., Aroda, V. R., Blonde, L., Guyot, P., Shaunik, A., Fazeli, M. S., Goswami, H. H., Kalra, S., & Pourrahmat, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14136 · Cited by 14
“However, evidence suggests that about 50% of people discontinue GLP-1RA therapy within 1 year,(3) and inadequate glycaemic control is the most commonly reported reason, by individuals, for discontinuing therapy.(4) The ADA and EASD recommend the addition of basal insulin in those inadequately controlled on GLP-1RAs.”
BackgroundChen, M., Zhao, N., Shi, W., Xing, Y., Liu, S., Meng, X., Li, L., Zhang, H., Meng, Y., Xie, S., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf005 · Cited by 17
Epidemiology of cardiovascular–kidney–metabolic syndrome
Mavromatis, L. A., & Grams, M. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01078-w · Cited by 14
Patil, M., Casari, I., Warne, L. N., & Falasca, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116245 · Cited by 12
Metadata
- Authors
- Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V.
- Affiliations
- GlaxoSmithKline (United States) (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Adelphi Group (United Kingdom) (GB)
- Corresponding author
- Sikirica, Mirko
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-09
- Volume
- Volume 10
- Pages
- 403-412
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC5630073
- OpenAlex
- W2763255780
- Cited by
- 223
- References
- 21
- Citations by year
- 2026: 40 · 2025: 54 · 2024: 34 · 2023: 23 · 2022: 21 · 2021: 22 · 2020: 13 · 2019: 11 · 2018: 5
- FWCI
- 6.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, drug discontinuation, medication adherence, gastrointestinal adverse effects, nausea and vomiting, physician-patient communication, patient expectations, weight gain, physician perceptions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.